MetaCap

Evotec SE ADR (EVO)

NASDAQ: EVOHealth CareBiotechnology: Pharmaceutical PreparationsUSD

1.32-0.13 (-8.97%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

EVO stock chart

Technical analysis

Key statistics

All statistics
Market cap
$469.11M
EPS (TTM)
-$0.59
52-week range
1.32 – 3.87
Day range
1.32 – 1.38
Volume / Avg
77.59K / 109.16K
Beta
—

52-week range

$1.32$3.87

EVO stock today

Evotec (EVO) closed at $1.32 on Nov 20, down 8.97% (-$0.13), versus the S&P 500's 3.70% decline. At this level, EVO sits near the bottom of its 52-week range of $1.32 to $3.87: 65.9% below the high, set on Jan 13, 2026 and 0.0% above the low. EVO is down 57.1% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 55.6%.

Evotec has posted a net loss over the last twelve months (EPS of -$0.59), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Evotec

Company profile

Evotec SE operates as a drug discovery and development company in the United States, Germany, France, the United Kingdom, Switzerland, and internationally. It operates in two segments, Shared R&D and Just – Evotec Biologics. The company is developing pharmaceutical products in various therapeutic areas, such as oncology, autoimmune, cancer, diabetes, heart failure, immunology, pain and inflammation, infectious, kidney, liver, respiratory, fibrotic and metabolic diseases, and rare diseases.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Dr. Christian Wojczewski Ph.D.
Headquarters
Hamburg
Employees
4,379
IPO year
2021
Website
evotec.com

Analyst forecast

Forecast

Consensus (3 analysts)

buy

Avg. price target

$4.45+237.12%

  • Strong buy 1
  • Buy 1
  • Hold 1
  • Sell 0
  • Strong sell 0

Target range

Low $1.95High $6.52

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

EVO news

All EVO news

Evotec peers

Health Care sector
EVO peer companies
CompanyPrice% ChgMarket capCompare
MNPRMonopar Therapeutics Inc.69.00-1.84%$467.60Mvs EVO
RZLTRezolute Inc.3.92-6.67%$465.58Mvs EVO
BLSMBlossomHill Therapeutics Inc.14.51+0.69%$461.20Mvs EVO
GYREGyre Therapeutics Inc.4.21-6.86%$460.79Mvs EVO
NGNENeurogene Inc.22.15-3.40%$458.53Mvs EVO
ASMBAssembly Biosciences Inc.22.19-1.38%$454.39Mvs EVO
STTKShattuck Labs Inc.4.46-1.98%$454.22Mvs EVO
HELPHelus Pharma Inc.6.11-9.88%$487.68Mvs EVO

Indexes, lists and sector

Evotec stock FAQ

What is Evotec's stock price today?

EVO last traded at $1.32 as of Nov 20, 4:00 PM EST, down 8.97% on the day. Prices are delayed at least 15 minutes.

Does Evotec pay a dividend?

No. Evotec does not currently pay a regular cash dividend.

Who is Evotec's CEO?

Dr. Christian Wojczewski Ph.D. is the chief executive officer of Evotec SE ADR, which has about 4,379 employees.

Has EVO ever split its stock?

Yes. The most recent EVO stock split was a 4-for-1 split on Oct 20, 2021, one of 2 splits on record.

What is the EVO 52-week high?

The 52-week high for EVO is $3.87 and the 52-week low is $1.32. The stock is currently 65.9% below its high.

Compare EVO